Compare REAX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAX | ENTA |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.3M | 382.7M |
| IPO Year | 2021 | 2012 |
| Metric | REAX | ENTA |
|---|---|---|
| Price | $1.71 | $11.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.49 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 3.5M | 204.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | $23.04 | $7.76 |
| Revenue Next Year | $15.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $1.58 | $6.44 |
| 52 Week High | $5.41 | $17.15 |
| Indicator | REAX | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 28.16 |
| Support Level | $1.63 | $10.21 |
| Resistance Level | $1.86 | $11.74 |
| Average True Range (ATR) | 0.10 | 0.75 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 48.21 | 4.51 |
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.